It has been almost two years since the FDA ordered online genetic testing firm 23andMe to stop offering its health screening service. Now, the company has jumped through all the necessary regulatory hoops to begin offering health data again. However, the service will be much more narrow in focus than what it was offering previously.
23andMe offers genetic testing kits for $199 (sometimes less when it’s on sale), and they’ve been available this whole time. The company has always offered ancestry analysis (e.g. where in the world your genes might come from) in addition to health screening, and that part of the service was unaffected by the FDA action. Prior to the FDA-mandated end of disease reporting, 23andMe would show users the estimated likelihood they would develop a certain disease — specifically, how their risk compared to the general population. For the full article click here
from health IT caucus http://ift.tt/1LHbTQF
via IFTTT
No comments:
Post a Comment